

**LAMANT Laurence, MD, PhD**  
**Full Professor of Pathology (1st class)**

Department of Pathology, Cancer University Institute Toulouse Oncopole, France  
Cancer Research Center of Toulouse, INSERM UMR1037, Team «RNA biology in haematological cancers»

**Tel : +33 5 15 31 61 97; Email: [lamant.l@chu-toulouse.fr](mailto:lamant.l@chu-toulouse.fr)**

***Medical Education***

---

2009	Full professor, Pathology, Toulouse, France
2007	Habilitation to conduct research programs (HDR), University Paul Sabatier, Toulouse, France
2002	PhD, Human Physiopathology : Immunomorphological and molecular study of Anaplastic Large Cell lymphomas. University Paul Sabatier, Human Physiopathology, Toulouse, France
1999- 2009	Associate professor, Pathology, Toulouse, France
1996	MD specialized in Pathology, Toulouse, France
1993-1994	Master's degree in Human Physiopathology, University Paul Sabatier, Toulouse, France
1991-1996	Medical assistant
1985-1990	Medical resident

***Awards***

---

2012	National Academy of Medicine Award
1997	Marie-Françoise d'Agay Award, Hematopathology
1997	Medical School Laureate

***Teaching responsibilities***

---

- Coordinator of the teaching of Pathology at the UFR medicine Purpan, Toulouse
- Teaching of molecular pathology at the University Paul Sabatier (Master, Oncology; “diplôme inter universitaire de pathologie moléculaire”)

***Clinical responsibilities***

---

- Head of the NGS platform at the Toulouse Hospital: Screening for actionable somatic mutations by targeted capture (solid tumor, lymphomas and liquid biopsies); TMB (TSO500 Illumina) ; clonality assessment (BIOMED-2 analysis)
- Head of the Dermatopathology sector in the Department of Pathology

***Learned societies and groups of experts***

---

- Member of the French Society of Pathology
- Member of the Cutaneous Lymphoma French Study Group
- Member and Secretary of the French Club of Dermatopathology

***Board member***

---

- Scientific committee of ARC French Foundation for cancer research
- Scientific committee of French League against cancer

- Scientific committee of Fondation de France
- Scientific committee of the French Society of Pediatrics

### ***Reviewer-Editorial board***

---

- Human Pathology, Haematologica, Blood, Histopathology
- Editorial board of « Cancers » Journal

### ***Peer Review Publications***

---

h-index: 45

More than 200 publications and 100 papers in different journals such as: Blood, Am J Pathol, Oncogene, J Clin Oncol, J Clin Invest, Leukemia, Mol Cancer Res, Haematologica, Human Pathol

### **Most important publications in the field**

- **Lamant L**, Meggetto F, al Saati T, Brugieres L, de Paillerets BB, Dastugue N, Bernheim A, Rubie H, Terrier-Lacombe MJ, Robert A, Rigal F, Schlaifer D, Shiuta M, Mori S, Delsol G. High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. *Blood*. 1996; 87:284-91
- **Lamant L**, Dastugue N, Pulford K, Delsol G, Mariamé B. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1 ;2) (q25;23) translocation. *Blood* 1999; 93: 3088-95
- Gascoyne RD, **Lamant L**, Martin-Subero JI, Lestou VS, Harris NL, Müller-Hermelink HK, Seymour JF, Horsman DE, Auvigne I, Espinos E, Siebert R, Delsol G. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements : report of six cases. *Blood* 2003; 102:2568-73
- **Lamant L**, Gascoyne RD, Duplantier MM, Armstrong F, Raghav A, Chhanabhai M, Rajcan-Separovic E, Raghav J, Delsol G, Espinos E. Non-muscle myosin heavy chain (MYH9) : A new partner fused to ALK in Anaplastic Large Cell Lymphoma. *Gene Chromosomes & Cancer* 2003; 37:427-32
- **Lamant L**, Espinos E, Duplantier M , Dastugue N, Robert A , Allouche M, Ragab J, Brousset P, Villalva C, Gascoyne RD, Al Saati T, Delsol G. Establishment of a novel anaplastic large cell lymphoma-cell line (COST) from a "small cell variant" of LAGC. *Leukemia* 2004; 18:1693-8
- Pulford K, **Lamant L**, Espinos E, Jiang Q, Xue L, Turturro F., Delsol G., Morris S.W. The emerging normal and disease-related roles of anaplastic lymphoma kinase. *Cell Mol Life Sci* 2004; 61:2939-53
- **Lamant L**, De Reynies A, Duplantier MM, Rickman DS, Sabourdy F, Giuriato S, Brugieres L, Gaulard P, Espinos E, Delsol G. Gene expression profiling of systemic anaplastic large cell lymphoma reveals differences depending on ALK status and two distinct morphological ALK+ subtypes. *Blood* 2007; 109:2156-64
- Chan JK, **Lamant L**, Algar E, Delsol G, Tsang WY, Lee KC, Tiedemann K, Chow CW. ALK+ histiocytosis: A novel type of systemic histiocytic proliferative disorder of early infancy. *Blood* 2008; 112:2965-8.
- **Lamant L**, Pileri S, Sabattini E, Brugières L, Jaffe ES, Delsol G. Cutaneous presentation of ALK-positive anaplastic large cell lymphoma following insect bites: evidence for an association in five cases. *Haematologica*. 2010;95:449-55.
- Desjobert C, Renalier MH, Bergalet J, Joseph N, Kruczynski A, Soulier J, Dejean E, Espinos E, Meggetto F, Cavallé J, Delsol G, **Lamant L**. MiR-29a down-regulation in ALK-positive Anaplastic Large Cell Lymphomas contributes to apoptosis blockade through Mcl-1 overexpression. *Blood* 2011; 117:6627-37
- **Lamant L**, McCarthy K, d'Amore E, Klapper W, Nakagawa A, Fraga M, Maldyk J, Simonitsch-Klupp I, Oschlies I, Delsol G, Mauguén A, Brugières L, Le Deley MC. Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study. *J Clin Oncol*. 2011;29:4669-76.

- Laurent C, Lopez C, Desjobert C, Berrebi A, Damm-Welk C, Delsol G, Brousset P, **Lamant L**. Circulating t(2;5)-positive cells can be detected in cord blood of healthy newborns. *Leukemia*. 2012;26:188-90.
- Kruczynski A, Delsol G, Laurent C, Brousset P, **Lamant L**. Anaplastic lymphoma kinase as a therapeutic target. *Expert Opin Ther Targets*. 2012;16:1127-38.
- Oeschlies I, Lisfeld J, **Lamant L**, Nakazawa A, d'Amore ES, Hansson U, Hebeda K, Simonitsch-Klupp I, Maldyk J, Müllauer L, Tinguely M, Stücker M, Ledele MC, Siebert R, Reiter A, Brugières L, Klapper W, Woessmann W. ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study. *Haematologica*. 2013;98:50-6
- Hoareau-Aveilla C, Valentin T, Daugrois C, Quelen C, Mitou G, Quentin S, Jia J, Spicuglia S, Ferrier P, Ceccon M, Giuriato S, Gambacorti-Passerini C, Brousset P, **Lamant L**, Meggetto F. Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth. *J Clin Invest*. 2015;125:3505-18.
- Bonzhaim I, Steinhilber J, Fend F, **Lamant L\***, Quintanilla-Martinez L\* (co-senior authors). ALK-positive anaplastic large cell lymphoma: an evolving story. *Front Biosci*. 2015;7:248-59.
- Laurent C, Delas D, Gaulard P, Haioun C, Moreau A, Xerri L, Traverse-Glehen A, Rousset T, Quintin-Roue I, Petrella T, Emile JF, Amara N, Rochaix P, Chenard-Neu MP, Tasei AM, Menet E, Chomarat H, Costes V, Andrac-Meyer L, Michiels JF, Chassagne-Clement C, de Leval L, Brousset P, Delsol G, **Lamant L**. Breast Implant Associated Anaplastic Large cell Lymphoma: two distinct clinicopathological variants with different outcomes. *Ann Oncol* 2016;27:306-14
- Malcolm T\*, Villarese\* P, Fairbairn C, **Lamant L**, Trinquand A, Hook CE, Burke GA, Brugières L, Hughes K, Payet D, Merkel O, Schiefer AI, Mian S, Wasik M, Turner M, Kenner L, Asnafi V, Macintyre E, Turner SD. NPM-ALK mimics thymic pre-T cell receptor (TCR) expansion but requires transient TCR expression for thymic egress and peripheral Anaplastic Large Cell Lymphoma development. *Nat Comm* 2016;7:10087 (\*: co-first authors)
- Turner SD, **Lamant L**, Kenner L, Brugieres L. Anaplastic Large Cell Lymphoma. *Br J Haematol* 2016 ; 173 :560-72
- Hoareau-Aveilla C, Quelen C, Congras A, Caillet N, Labourdette D, Dozier C, Brousset P, **Lamant L**, Meggetto F. miR-497 suppresses cycle progression through an axis involving CDK6 in ALK-positive cells. *Haematologica*. 2019;104:347-59.
- Sibon D, Nguyen DP, Schmitz N, Suzuki R, Feldman AL, Gressin R, **Lamant L**, Weisenburger DD, Rosenwald A, Nakamura S, Ziepert M, Maurer MJ, Bast M, Armitage JO, Vose JM, Tilly H, Jais JP, Savage KJ. ALK-positive anaplastic large-cell lymphoma: an international, individual patient data pooled analysis of 263 adults. *Haematologica*. 2019;104:e562-e565.
- Mussolin L, Le Deley MC, Carraro E, Damm-Welk C, Attarbaschi A, Williams D, Burke A, Horibe K, Nakazawa A, Wrobel G, Mann G, Csóka M, Uyttebroeck A, Fernández-Delgado Cerdá RF, Beishuizen A, Mellgren K, Burkhardt B, Klapper W, Turner SD, D'Amore ESG, **Lamant L**, Reiter A, Woessmann W, Brugières L, Pillon M. Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial. *Cancers* 2020;12:E2747.
- Congras A, Hoareau-Aveilla C, Caillet N, Tosolini M, Villarese P, Cieslak A, Rodriguez L, Asnafi V, Macintyre E, Egger G, Brousset P, **Lamant L**, Meggetto F. ALK-transformed mature T lymphocytes restore early thymus progenitor features. *J Clin Invest*. 2020 1;130:6395-6408
- Del Baldo G, Abbas R, Woessmann W, Horibe K, Pillon M, Burke A, Beishuizen A, Rigaud C, Le Deley MC, **Lamant L**, Brugières L. Neuro-meningeal relapse in anaplastic large-cell lymphoma: incidence, risk factors and prognosis - a report from the European intergroup for childhood non-Hodgkin lymphoma. *Br J Haematol*. 2021;192:1039-1048
- Rigaud C, Abbas R, Grand D, Minard-Colin V, Aladjidi N, Buchbinder N, Garnier N, Plat G, Couec ML, Duplan M, Lambilliotte A, Schmitt C, Leblanc T, **Lamant L**, Brugières L. Should treatment of ALK-positive anaplastic large cell lymphoma be stratified according to minimal residual disease? *Pediatr Blood Cancer*. 2021;68:e28982.

- Menguy S, Mansour Y, Jullié ML, Augereau O, Ortonne N, Balme B, Battistella M, **Lamant L**, Beltzung F, Szablewski V, Gaulard P, Bagot M, Beylot-Barry M, Vergier B. Impact of algorithms proposed by the Cutaneous Lymphoma French Study Group for diagnosis of cutaneous lymphoproliferations. *Ann Pathol*. 2021;41:290-9.

- Quelen C, Grand D, Sarot E, Brugières L, Sibon D, Pradines A, Laurent C, Brousset P, **Lamant L**. Minimal Residual Disease Monitoring Using a 3'ALK Universal Probe Assay in ALK-Positive Anaplastic Large-Cell Lymphoma: ddPCR, an Attractive Alternative Method to Real-Time Quantitative PCR. *J Mol Diagn*. 2021; 23:131-9

### **Book chapters**

---

- Delsol G, Al Saati T, **Lamant L**, Selves J, Brousset P. Classification histopathologique, immunologique, cytogénétique et moléculaire des lymphomes malins non hodgkiniens. *Encyclopédie Médico-chirurgicale* 1998 ;13-016-A-15.

- Delsol G, Al Saati T, **Lamant L**, Brousset P. Maladie de Hodgkin : Biologie de la cellule de Reed-Sternberg. Solal-Céligny P, Brousse N, Fermé C, Gisselbrecht C, Reyes F, Coiffier B. *Lymphomes : Lymphomes non hodgkiniens- Maladie de Hodgkin*. 3<sup>e</sup> Ed. Editions Frison-Roche. 1997

-Delsol G, Espinos E, Giuriato S, **Lamant L**. Anaplastic Large Cell Lymphoma (LAGC). - In *Macgrath*: “The non-Hodgkin’s lymphomas”. 3<sup>e</sup> Edition

- Russano de Paiva G, Laurent C, **Lamant L**, Delsol G, Brousset P. Classification histopathologique, immunologique, cytogénétique et moléculaire des lymphomes non hodgkiniens. *Encyclopédie Médico-chirurgicale* 2009.

- Delsol G, **Lamant L**, Brousset P. Anaplastic large cell lymphoma, ALK-positive and anaplastic large cell lymphoma, ALK-negative. In *Hematopathology* 2009

- **Lamant L**, Feldman A, Delsol G, Brousset P. ALK-positive and anaplastic large cell lymphoma, ALK-negative, In: Jaffe ES, Harris NL, Vardiman JW, Campo E, Arber DA. Eds Elsevier.

*Hematopathology* 2015

- **Lamant L**. Anaplastic Large Cell Lymphomas. In: *Encyclopedia of Pathology*. Ed van Krieken H; Molina T, section ed. Springer. 2015

- **Lamant L**, Gaulard P, Chan JKC, Jaffe ES, Nakamura S, Molina TJ, de Leval L. Anaplastic large cell lymphoma and other rare mature T- and NK-cell lymphomas. *WHO Classification of Tumors of the lung pleura thymus and heart*. Lyon, IARC, 2016 pp 275-276

-Falini B, **Lamant L**, Campo E, Jaffe ES, Gascoyne RD, Stein H, Müller-Hermelink HK, Kinney MC. Anaplastic large cell lymphoma, ALK positive. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., eds. *WHO Classification of Tumors of hematopoietic and lymphoid tissues*. Lyon, IARC, 2017, pp 413-418

- **Lamant L**, d’Amore E, Onciu M, Nakagawa A. Anaplastic large cell lymphoma, ALK-positive *WHO Classification of Paediatric Tumours* 5th edition, Lyon, IARC, 2021 (in press)

- **Lamant L**, d’Amore E, Onciu M. ALK-positive Large B-cell lymphoma. *WHO Classification of Paediatric Tumours* 5th edition, Lyon, IARC, 2021 (in press)

### **Patents**

---

Colacios-Viatgé C, Imbert C, Segui B, Meyer N, **Lamant-Rochaix L**, Levade T, Andrieu-Abadie N. “Use of SK1 as biomarker for predicting response to immune checkpoint inhibitors”. WO2019162325 (date publication: 29.08.2019)

---